Completed PHASE2/PHASE3 INTERVENTIONAL 2-arm NCT00565331

Rituximab for Prevention of Rejection After Renal Transplantation

A Prospective Randomized Study on the Efficacy and Safety of the Prophylactic Use of Rituximab, Added to Standard Immunosuppressive Treatment in Comparison With Standard Immunosuppressive Treatment Alone in Renal Transplantation

Sponsor: Astellas Pharma GmbH

Conditions Kidney Transplantation

Interventions Placebo Rituximab

Updated 6 times since 2017 Last updated: Nov 9, 2015 Started: Dec 31, 2007 Primary completion: Dec 31, 2013 Completion: Jun 30, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00565331, this PHASE2/PHASE3 trial focuses on Kidney Transplantation and remains completed. Sponsored by Astellas Pharma GmbH, it has been updated 6 times since 2007, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2/PHASE3

Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Mar 2022 — Jul 2024 [monthly]

Completed PHASE2_PHASE3
Jan 2021 — Mar 2022 [monthly]

Completed PHASE2_PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2_PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2_PHASE3

First recorded

Dec 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Astellas Pharma GmbH
Hoffmann-La Roche
Radboud University Medical Center

Data source: Radboud University Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Nijmegen, Netherlands